Compass Therapeutics Stock Investor Sentiment
| CMPX Stock | USD 2.24 0.02 0.88% |
Slightly above 59% of all Compass Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Compass Therapeutics suggests that some traders are interested. Compass Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Compass Therapeutics' earnings reports, geopolitical events, and overall market trends.
Compass |
Compass Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Compass Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Compass Therapeutics that are available to investors today. That information is available publicly through Compass media outlets and privately through word of mouth or via Compass internal channels. However, regardless of the origin, that massive amount of Compass data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Compass Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Compass Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Compass Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Compass Therapeutics alpha.
Compass Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 58054 shares by Schuetz Thomas J. of Compass Therapeutics at 1.86 subject to Rule 16b-3 | 01/08/2025 |
2 | Why Compass Therapeutics Inc Is Skyrocketing So Far In 2025 - Yahoo Finance | 02/03/2025 |
3 | Why Compass Therapeutics Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
4 | Disposition of 41687 shares by Schuetz Thomas J. of Compass Therapeutics at 3.5 subject to Rule 16b-3 | 02/07/2025 |
5 | Compass Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock | 02/10/2025 |
6 | ADAGE CAPITAL PARTNERS GP, L.L.C. Reduces Stake in Compass Therapeutics Inc | 02/12/2025 |
7 | Acquisition by Shin Barry of 250000 shares of Compass Therapeutics at 3.65 subject to Rule 16b-3 | 02/13/2025 |
8 | Compass Therapeutics Shares Down 7.6 percent - Should You Sell - MarketBeat | 02/14/2025 |
9 | Piper Sandler Begins Coverage on Compass Therapeutics - MarketBeat | 02/20/2025 |
10 | Insider Trading | 02/26/2025 |
11 | Acquisition by Gray Mary Ann of 45000 shares of Compass Therapeutics subject to Rule 16b-3 | 02/28/2025 |
12 | Stifel maintains Compass Therapeutics stock Buy rating, 10 target - Investing.com | 03/10/2025 |
13 | Acquisition by Schuetz Thomas J. of 30000 shares of Compass Therapeutics at 2.83 subject to Rule 16b-3 | 03/11/2025 |
14 | With 42 percent stake, Compass Therapeutics, Inc. seems to have captured institutional investors interest | 03/18/2025 |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.